Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Type 2 diabetes: PIONEER REAL Switzerland study

Semaglutide in oral form convinces in everyday practice

    • Congress Reports
    • Education
    • Endocrinology and Diabetology
    • Market & Medicine
    • RX
    • Studies
  • 3 minute read

In the non-interventional PIONEER REAL Switzerland study, adult type 2 diabetics treated with oral semaglutide as part of routine clinical care achieved clinically significant improvement in glycemic control with no new safety signals. The results were presented at the SGED Annual Meeting and underpin the promising results of the clinical approval studies.

Semaglutide has also been on the market in Switzerland for the treatment of type 2 diabetes (T2D) in oral form since 2020 – under the trade name Rybelsus® [1]. Like other glucagon-like peptide-1 receptor agonists (GLP-1-RA), semaglutide binds to the GLP-1 receptor, thereby promoting insulin secretion and inhibiting glucagon secretion. The Phase III PIONEER trial program was very successful. One of the main studies showed that Rybelsus® not only improves metabolic control and reduces body weight, but also results in fewer heart attacks and even fewer deaths[1,2]. The aim of the international Phase IV study PIONEER REAL is to systematically observe how the drug works and is tolerated under everyday conditions [2].

Multicenter real-world study

PIONEER REAL Switzerland is part of a study project conducted in 13 countries – it is a 34-44-week single-arm, prospective open-label multicenter study in adults with T2D. Participants were treatment-naive to glucose-lowering injection therapies at baseline and received semaglutide in oral form once daily as part of their usual routine care [3]. In addition to changes in HbA1c (primary endpoint) and body weight (secondary endpoint), the proportion of patients who achieved HbA1c <7% and/or a composite endpoint of an HbA1c reduction ≥1% accompanied by a reduction in body weight (BW) ≥3% or ≥5% at the end of the study was recorded.

Important results at a glance

Of the 185 participants included, 90.8% completed the study and 77.3% remained on semaglutide therapy until the end of the study [3]. At baseline, the average age was 62 (SD 10.4) years, the HbA1c value was 7.7% (SD 1.5%) and the body weight was 95.6 kg (SD 17.6 kg). The mean BMI was documented as 33.2 kg/m2 (4.8 kg/m2). 56.2% of the participants received other glucose-lowering medication at the same time.

** SD = standard deviation
KI=confidence interval

The estimated mean changes from baseline to the end of the study were as follows [3]:

  • HbA1cvalues: change of -0.9% (95% CI: -1.1; -0.7, p<0.0001)
  • Absolute body weight: change of 4.7 kg (95% CI: -5.6; -3.8, p<0.0001)
  • Relative body weight: reduction of -4.9% (95% CI: -5.7; -4.0, both p<0.0001)
  • At the end of the study, 64.2% of the participants had an HbA1c value <7% and 37.8% and 28.3% achieved the composite endpoint of an HbA1c reduction ≥1% plus a KG reduction ≥3% and ≥5% respectively.

A total of 139 adverse events (AEs) were reported in 65 participants (35.1%) [3]. Most were mild or moderate, with gastrointestinal disorders being the most common (89 events in 50 participants). 31 AEs in 20 (10.8%) participants led to discontinuation of oral semaglutide. A total of six serious AEs were reported, which were probably not related to Semaglutide treatment.

Source: Novo Nordisk

Literature:

  1. Swissmedic: Arzneimittelinformation,
    www.swissmedicinfo.ch, (last accessed 11/21/2023)
  2. Husain M, et al.: PIONEER 6 Investigators. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. NEJM 2019; 381(9): 841–851.
  3. Kick A, et al.: Real-world use of oral semaglutide in adults with type 2 diabetes: Results from the PIONEER REAL Switzerland multicenter, prospective, observational study. Abstractband, Annual Meeting SGED/SSED, 16. –17.11.2023.

CARDIOVASC 2023; 22(4): 58
HAUSARZT PRAXIS 2023: 18(12): 37

Autoren
  • Mirjam Peter, M.Sc.
Publikation
  • CARDIOVASC
  • HAUSARZT PRAXIS
Related Topics
  • Form of administration
  • glycemic control
  • oral semaglutide
  • Pioneer Real
  • Rybelsus
  • Semaglutide
  • Swiss Society for Endocrinology and Diabetology
  • Type 2 diabetes
Previous Article
  • Mild cognitive impairment (MCI): neuroprotective factors

Flavonoids have an antioxidant effect

  • Education
  • RX
  • Studies
View Post
Next Article
  • Influenza season 2023/24

Current protection options for particularly vulnerable people

  • General Internal Medicine
  • Infectiology
  • Market & Medicine
  • Pneumology
  • Prevention and health care
  • RX
View Post
You May Also Like
View Post
  • 15 min
  • Current status and future prospects

Cell and gene therapies in modern cardiology

    • Cardiology
    • Education
    • Genetics
    • RX
    • Studies
View Post
  • 14 min
  • Patient-oriented recommendations for action

Effect of heat on diabetes technology

    • RX
    • CME continuing education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Prevention and health care
    • Studies
View Post
  • 19 min
  • Cardiovascular risk and obesity

Pathomechanisms, secondary prevention and treatment options

    • RX
    • Cardiology
    • CME continuing education
    • Endocrinology and Diabetology
    • Nutrition
    • Sports Medicine
    • Studies
    • Training with partner
View Post
  • 6 min
  • Ventricular arrhythmias

Indication for ICD or WCD?

    • RX
    • Cardiology
    • Congress Reports
    • General Internal Medicine
    • Studies
View Post
  • 3 min
  • Early breast cancer

Overweight and obesity worsen the prognosis

    • Congress Reports
    • Gynecology
    • Oncology
    • Prevention and health care
    • RX
    • Studies
View Post
  • 8 min
  • Psoriasis treatment with biologics

What are the latest trends?

    • Congress Reports
    • Dermatology and venereology
    • Pharmacology and toxicology
    • Rheumatology
    • RX
    • Studies
View Post
  • 4 min
  • Flu vaccination for older people

Benefit of the high-dose influenza vaccine

    • Congress Reports
    • General Internal Medicine
    • Geriatrics
    • Infectiology
    • RX
    • Studies
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Pathomechanisms, secondary prevention and treatment options
  • 2
    Effect of heat on diabetes technology
  • 3
    Improved quality of care aims for satisfied patients
  • 4
    Dr. ChatGPT: Large language models in everyday clinical practice
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.